In 2022, the Europe Phase IV clinical trials market had a valuation of USD 2.58 billion. It is anticipated that the market will experience growth, increasing from USD 2.71 billion in 2023 to USD 3.84 billion by 2030. This growth is expected to demonstrate a Compound Annual Growth Rate (CAGR) of 5.1% over the forecast period.

In 2022, the Europe Phase IV clinical trials market had a valuation of USD 2.58 billion. It is anticipated that the market will experience growth, increasing from USD 2.71 billion in 2023 to USD 3.84 billion by 2030. This growth is expected to demonstrate a Compound Annual Growth Rate (CAGR) of 5.1% over the forecast period.